Compare Repligen Corporation Common Stock (RGEN) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Vertex Pharmaceuticals Incorporated — how do they compare? Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B), while Vertex Pharmaceuticals Incorporated trades at $507.51 (market cap $126.35B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 11.2× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| RGEN | VRTX | |
|---|---|---|
Market Cap | $11.31B | $126.35B |
Volume | 1,216,919 | 2,089,984 |
Sector | Health | Health |
52-Week High | $194.57 | $557.96 |
52-Week Low | $102.87 | $407.90 |
Typical Hold Time | 0 Days | 120 Days |
Enterprise Value | $11.20B | $120.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Vertex Pharmaceuticals (VRTX) trades at $485.22, down 4.3% amid a bearish technical signal, though fundamentals remain strong with 2025 revenue of $12.0B and net income of $3.95B. The company maintains dominant cystic fibrosis market position and shows positive Phase II data for kidney disease drug inaxaplin. Analyst consensus is strongly bullish with 85.7% buy ratings and $573.50 price target, representing 18% upside potential from current levels.
Vertex presents a compelling growth story with robust profitability (35% net margin) and expanding pipeline, though recent earnings misses and competitive pressures warrant caution. The stock's current dip may offer entry opportunity for long-term investors, with key catalysts including regulatory decisions and pipeline advancements expected in early 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
